🇺🇸 FDA
Pipeline program

A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)

CLN-978-RA-101

Phase 1 other active

Quick answer

A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) for Treatment-Refractory Rheumatoid Arthritis is a Phase 1 program (other) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Cullinan Therapeutics
Indication
Treatment-Refractory Rheumatoid Arthritis
Phase
Phase 1
Modality
other
Status
active

Clinical trials